• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从中皮素前体裂解而来的巨核细胞增强因子是间皮瘤患者血清中一种有用的肿瘤标志物。

Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.

作者信息

Onda Masanori, Nagata Satoshi, Ho Mitchell, Bera Tapan K, Hassan Raffit, Alexander Richard H, Pastan Ira

机构信息

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA.

出版信息

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31. doi: 10.1158/1078-0432.CCR-06-0472.

DOI:10.1158/1078-0432.CCR-06-0472
PMID:16857795
Abstract

PURPOSE

To establish monoclonal antibodies (mAb) against megakaryocyte potentiation factor (MPF) and detect MPF in the blood of patients with mesothelioma.

EXPERIMENTAL DESIGN

Mice were immunized with a purified recombinant human MPF-rabbit-Fc fusion protein and with MPF. Several hybridomas producing mAbs to MPF were established. A double-determinant (sandwich) ELISA was constructed using mAbs to two different epitopes and used to determine if MPF is present in the serum of patients with mesothelioma.

RESULTS

We established seven anti-MPF mAbs whose topographical epitopes were classified into three nonoverlapping groups. All the mAbs reacted with recombinant MPF protein by ELISA. One of the mAbs detected MPF and the mesothelin precursor protein containing MPF in cell lysates on Western blotting. A sandwich ELISA using mAbs to two different epitopes was constructed and used to measure the presence of MPF in the media of various mesothelin-expressing cancer cell lines and in human serum. The ELISA showed that MPF levels were elevated in 91% (51 of 56) of patients with mesothelioma compared with healthy controls. Furthermore, serum MPF fell to normal levels in two patients after surgery for their peritoneal mesothelioma.

CONCLUSIONS

Using new mAbs to MPF, we showed that MPF is secreted by several mesothelioma cell lines and is frequently elevated in the blood of patients with mesothelioma. Measurement of MPF may be useful in following the response of mesothelioma to treatment.

摘要

目的

制备抗巨核细胞增强因子(MPF)的单克隆抗体(mAb),并检测间皮瘤患者血液中的MPF。

实验设计

用纯化的重组人MPF-兔-Fc融合蛋白和MPF免疫小鼠。建立了几种产生抗MPF单克隆抗体的杂交瘤细胞系。使用针对两个不同表位的单克隆抗体构建双抗原夹心法ELISA,用于检测间皮瘤患者血清中是否存在MPF。

结果

我们制备了7种抗MPF单克隆抗体,其拓扑表位分为3个不重叠的组。所有单克隆抗体通过ELISA与重组MPF蛋白反应。其中一种单克隆抗体在蛋白质印迹法中检测到细胞裂解物中的MPF和含MPF的间皮素前体蛋白。构建了使用针对两个不同表位的单克隆抗体的夹心ELISA,用于检测各种表达间皮素的癌细胞系培养基和人血清中MPF的存在。ELISA结果显示,与健康对照相比,91%(56例中的51例)间皮瘤患者的MPF水平升高。此外,两名腹膜间皮瘤患者术后血清MPF降至正常水平。

结论

利用针对MPF的新型单克隆抗体,我们发现MPF由几种间皮瘤细胞系分泌,且在间皮瘤患者血液中经常升高。检测MPF可能有助于监测间皮瘤的治疗反应。

相似文献

1
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.从中皮素前体裂解而来的巨核细胞增强因子是间皮瘤患者血清中一种有用的肿瘤标志物。
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31. doi: 10.1158/1078-0432.CCR-06-0472.
2
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.巨核细胞增强因子作为恶性胸膜间皮瘤的肿瘤标志物:与间皮素相比的评估
Lung Cancer. 2008 Oct;62(1):45-54. doi: 10.1016/j.lungcan.2008.02.012. Epub 2008 Apr 3.
3
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.血清间皮素的检测与定量,间皮素是一种用于间皮瘤和卵巢癌患者的肿瘤标志物。
Clin Cancer Res. 2006 Jan 15;12(2):447-53. doi: 10.1158/1078-0432.CCR-05-1477.
4
Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.用于检测N-ERC/间皮素的灵敏且特异的新型酶联免疫吸附测定法提高了其作为间皮瘤有用血清肿瘤标志物的潜力。
Clin Cancer Res. 2008 Mar 1;14(5):1431-7. doi: 10.1158/1078-0432.CCR-07-1613.
5
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.可溶性间皮素和巨核细胞促进因子在间皮瘤中的诊断性能。
Am J Respir Crit Care Med. 2010 Mar 15;181(6):620-5. doi: 10.1164/rccm.200907-1020OC. Epub 2010 Jan 14.
6
Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.建立针对人ERC/间皮素的新型单克隆抗体,用于研究和诊断表达ERC/间皮素的癌症。
Pathol Int. 2009 Mar;59(3):161-6. doi: 10.1111/j.1440-1827.2009.02344.x.
7
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.新型间皮素单克隆抗体,可用于免疫组织化学、荧光激活细胞分选、蛋白质免疫印迹法及酶联免疫吸附测定。
Clin Cancer Res. 2005 Aug 15;11(16):5840-6. doi: 10.1158/1078-0432.CCR-05-0578.
8
A recombinant polypeptide of the megakaryocyte potentiating factor is a potential biomarker in plasma for the detection of mesothelioma.巨核细胞增强因子的重组多肽是血浆中用于检测间皮瘤的潜在生物标志物。
Biochem Biophys Res Commun. 2017 Apr 29;486(2):526-532. doi: 10.1016/j.bbrc.2017.03.077. Epub 2017 Mar 19.
9
Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.可溶性间皮素、巨核细胞增强因子和骨桥蛋白作为间皮瘤患者反应和预后的标志物。
J Thorac Oncol. 2011 Nov;6(11):1930-7. doi: 10.1097/JTO.0b013e3182272294.
10
Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.人胰腺导管癌中N-ERC/间皮素的分泌及C-ERC/间皮素的表达
Oncol Rep. 2008 Dec;20(6):1375-80.

引用本文的文献

1
Characterization of mesothelin gene expression in dogs and overexpression in canine mesotheliomas.犬中皮素基因表达的特征及在犬间皮瘤中的过表达
Front Vet Sci. 2024 Sep 9;11:1436621. doi: 10.3389/fvets.2024.1436621. eCollection 2024.
2
Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma.间皮瘤患者和非间皮瘤患者的血清N-ERC/Mesothelin和C-ERC/Mesothelin水平及临床病理因素
Juntendo Iji Zasshi. 2023 Apr 14;69(2):124-136. doi: 10.14789/jmj.JMJ22-0042-OA. eCollection 2023.
3
Circulating biomarkers in malignant pleural mesothelioma.
恶性胸膜间皮瘤中的循环生物标志物
Explor Target Antitumor Ther. 2020;1(6):434-451. doi: 10.37349/etat.2020.00028. Epub 2020 Dec 28.
4
Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.用于恶性胸膜间皮瘤的基于血液的靶向蛋白质组学标志物的验证。
Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):1973-1982. doi: 10.1158/1055-9965.EPI-20-0543. Epub 2020 Jul 30.
5
Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases.间皮素增强新形成的胰腺腹膜转移瘤的血管生成。
Mol Cancer Res. 2020 Feb;18(2):229-239. doi: 10.1158/1541-7786.MCR-19-0688. Epub 2019 Nov 1.
6
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives.恶性胸膜间皮瘤中的液体活检:现状、陷阱与展望
Front Oncol. 2019 Aug 14;9:740. doi: 10.3389/fonc.2019.00740. eCollection 2019.
7
Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.间皮素、钙视网膜蛋白和巨核细胞增强因子作为恶性胸膜间皮瘤的生物标志物。
Lung. 2019 Oct;197(5):641-649. doi: 10.1007/s00408-019-00244-1. Epub 2019 Jul 2.
8
The human tubal lavage proteome reveals biological processes that may govern the pathology of hydrosalpinx.人类输卵管灌洗蛋白质组揭示了可能控制输卵管积水病理的生物学过程。
Sci Rep. 2019 Jun 20;9(1):8980. doi: 10.1038/s41598-019-44962-1.
9
Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer.血清巨核细胞增强因子升高作为间皮瘤和原发性肺癌患者生存不良的预测指标
J Appl Lab Med. 2018 Sep;3(2):166-177. doi: 10.1373/jalm.2017.025015.
10
Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma.巨核细胞增强因子作为恶性间皮瘤治疗的预测性生物标志物
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00282. Epub 2018 May 11.